http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
백질 고신호 병변이 경도인지장애 환자의 인지영역 기능 저하에 미치는 영향
구본대,박기정 대한치매학회 2011 Dementia and Neurocognitive Disorders Vol.10 No.1
Background: It is still unclear that white matter hyperintensities (WMH) would affect the specific cognitive decline of the patients with mild cognitive impairment (MCI). We explored whether WMH influence the specific cognitive decline to the patient with MCI. Methods: Patients with MCI were recruited from August 2005 to February 2009. We evaluated the degree of WMH by the combination of deep and periventricular WMH. Patients with MCI were divided into groups with minimal (Group I), moderate (Group II) and severe (Group III) hyperintensities by the degree of WMH. Being regarded as subcortical vascular MCI, the patients in the Group III were excluded. According to the affected cognitive domain, patients were divided into amnestic single, amnestic multiple, non-amnestic single and non-amnestic multiple MCI. Results: A total of 156 patients were recruited (118 in Group I and 38 in Group II). Mean score of MMSE was 24.9±3.1 and that of CDR was 0.5±0.1. The most frequent subtype was amnestic multiple MCI (67.9%). There were no differences in the affected cognitive domains and distribution of the MCI subtype between Group I and Group II. However, the frontal cognitive function declined significantly, in proportion to the increasing periventricular WMH. Conclusions: These results suggest that increasing of periventricular WMH may affect to the frontal cognitive decline in patients with MCI.
구본대,김신겸,이준영,박기형,신준현,김광기,윤영철,이영민,홍창형,서상원,나덕렬,김성윤,정해관,김도관,이재홍,김상윤,연병길,김수영,한설희 대한의사협회 2011 대한의사협회지 Vol.54 No.8
The Clinical Research Center for Dementia of South Korea (CREDOS), a nation-wide clinical dementia research group, has prepared clinical practice guidelines (CPG) for dementia tailored to the Korean population. In this article, a summary of the CREDOS CPG is presented with the Korean and English version of full report included in the appendix. The CREDOS CPG in intended not only for psychiatrists and neurologists, but also internists, family physicians, and other primary care physicians involved in the prevention and early diagnosis of dementia. While our CPG for dementia mainly covers Alzheimer's disease (AD) and vascular dementia (VaD), it also includes mild cognitive impairment (MCI) and vascular MCI, which are currently known to be the preclinical stages of AD or VaD, respectively, with emphasis placed on early diagnosis. The CREDOS CPG aims to achieve the following goals by developing CPG for dementia: to establish evidence-based, objective and clear clinical standards for dementia; to improve the clinical decision-making process for patients with dementia; to provide scientific and systematic scales to aid in the work of dementia specialists; to suggest comprehensive and systematic healthcare services tailored to each dementia subtype. The CREDOS CPG focuses on diagnosis and evaluation of clinical practice available domestically, and provides useful concepts of dementia. Its emphasis is on etiologies and epidemiology, diagnostic criteria and evaluation, neuropsychological tests, behavioral and psychological symptoms, the activities of daily living, laboratory tests,and brain imaging.
급성 뇌경색에서 시간 경과에 따른 혈청 신경원 특이 에놀라제(neuron specific enolase)의 변화
구본대,정경천 대한신경과학회 2009 대한신경과학회지 Vol.27 No.1
Background: Neuron-specific enolase (NSE) is a useful indicator of neuronal injury in acute cerebral infarction. We investigated the changes in serial serum NSE levels in patients with acute cerebral infarction. Methods: We measured serial serum NSE levels at 24, 48, 72, and 96 hours, and 2 weeks after the onset of cerebral infarction in 30 patients (15 territorial and 15 lacunar infarctions). We also measured the NSE levels in age-matched controls (n=15) who had no evidence of acute stroke or other neurological disorders. The NSE level was measured using a radioimmunoassay. Results: The initial serum NSE level was significantly higher in the cerebral infarction group than in the control group (6.6±2 vs 4.7±1.6 ng/mL [mean±SD], p=0.006). This difference was also observed between the territorial and lacunar infarction groups until 72 hours after the cerebral infarction. The serum NSE level peaked at 72 hours after the infarction in both lacunar and territorial infarction groups. The correlation between the NSE level and the score on the NIH Stroke Scale was strongest at 48 hours after the cerebral infarction (r=0.469). Conclusions: Serum NSE level can be a good indicator for distinguishing lacunar from territorial infarction during the acute stage of cerebral infarction. Background: Neuron-specific enolase (NSE) is a useful indicator of neuronal injury in acute cerebral infarction. We investigated the changes in serial serum NSE levels in patients with acute cerebral infarction. Methods: We measured serial serum NSE levels at 24, 48, 72, and 96 hours, and 2 weeks after the onset of cerebral infarction in 30 patients (15 territorial and 15 lacunar infarctions). We also measured the NSE levels in age-matched controls (n=15) who had no evidence of acute stroke or other neurological disorders. The NSE level was measured using a radioimmunoassay. Results: The initial serum NSE level was significantly higher in the cerebral infarction group than in the control group (6.6±2 vs 4.7±1.6 ng/mL [mean±SD], p=0.006). This difference was also observed between the territorial and lacunar infarction groups until 72 hours after the cerebral infarction. The serum NSE level peaked at 72 hours after the infarction in both lacunar and territorial infarction groups. The correlation between the NSE level and the score on the NIH Stroke Scale was strongest at 48 hours after the cerebral infarction (r=0.469). Conclusions: Serum NSE level can be a good indicator for distinguishing lacunar from territorial infarction during the acute stage of cerebral infarction.